It's been over a year since Babylon Health – once the darling of the UK digital health sector – foundered into bankruptcy and, in the meantime, former CEO Ali Parsa has not been idle.

Antibody-drug conjugates remain front and centre of the biopharma world. Following Enhertu’s historic agnostic approval in HER2-positive solid tumours and TIVDAK winning full approval, the field ...

MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/PD-L1 immunotherapy for ...

Roche’s gene therapy unit Spark has added to its pipeline in inherited retinal diseases (IRDs) with a $216 million alliance with Spanish biotech SpliceBio. Under the terms of the deal, Spark ...

In this instalment of our renewed clinical trials round-ups, we look at life sciences research and development announced during the week of 20th to 24th May, from early-stage onwards. During this ...

BCIs could emerge as a ground-breaking tool for the pharma industry, offering new ways to understand and treat complex conditions. By combining advanced technology with medical research, Ben ...

Bayer has joined its peers among European drugmakers with a hike in pharma forecasts for the year, as it recorded a rise in group sales, but lower profits for the second quarter. Total revenues ...

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping job losses. The company that made its name by providing saliva ...

Looking ahead, the momentum gained in 2024 must be maintained and amplified. By fostering a culture of belonging in the ...

My conclusion, having worked in various regions and corporate settings: don’t be loud. Be yourself. Be decent. Be ...

The transaction – announced on Christmas Eve – comes after WuXi AppTec has been thrust into the US political spotlight as a ...

The Pharmaceutical Research and Manufacturers of America (PhRMA) trade body is donating $1 million to fund President-elect ...